The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)



Gene Review

OAS1  -  2'-5'-oligoadenylate synthetase 1, 40/46kDa

Homo sapiens

Synonyms: (2-5')oligo(A) synthase 1, 2'-5'-oligoadenylate synthase 1, 2-5A synthase 1, E18/E16, IFI-4, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of OAS1


Psychiatry related information on OAS1


High impact information on OAS1


Chemical compound and disease context of OAS1


Biological context of OAS1


Anatomical context of OAS1


Associations of OAS1 with chemical compounds


Physical interactions of OAS1

  • The cells were returned to monolayer growth for 18 h, and then harvested and assayed to determine the amount of RNase L protein (via [32P]2-5A binding) and the specific activities of RNase L and 2-5A synthetase [28].

Regulatory relationships of OAS1

  • Lymphoblastoid Raji cells were insensitive to the antiviral and anticellular activities of IFN-alpha, beta and gamma, but 2-5A synthetase was induced in cells by the treatment with IFN-alpha and beta, though the enzyme level was lower than that found in interferon-treated Daudi cells [29].
  • We hypothesized that polymorphisms in the OAS1 gene could influence the susceptibility to MS [30].
  • 2-5A synthetase activity was significantly enhanced when the cells were treated with doses of TNF that afforded antiviral protection [31].

Other interactions of OAS1


Analytical, diagnostic and therapeutic context of OAS1


  1. Association of SARS susceptibility with single nucleic acid polymorphisms of OAS1 and MxA genes: a case-control study. He, J., Feng, D., de Vlas, S.J., Wang, H., Fontanet, A., Zhang, P., Plancoulaine, S., Tang, F., Zhan, L., Yang, H., Wang, T., Richardus, J.H., Habbema, J.D., Cao, W. BMC Infect. Dis. (2006) [Pubmed]
  2. Single nucleotide polymorphisms in genes for 2'-5'-oligoadenylate synthetase and RNase L inpatients hospitalized with West Nile virus infection. Yakub, I., Lillibridge, K.M., Moran, A., Gonzalez, O.Y., Belmont, J., Gibbs, R.A., Tweardy, D.J. J. Infect. Dis. (2005) [Pubmed]
  3. Vaccinia virus E3L protein is an inhibitor of the interferon (i.f.n.)-induced 2-5A synthetase enzyme. Rivas, C., Gil, J., Mĕlková, Z., Esteban, M., Díaz-Guerra, M. Virology (1998) [Pubmed]
  4. Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR. Knapp, S., Yee, L.J., Frodsham, A.J., Hennig, B.J., Hellier, S., Zhang, L., Wright, M., Chiaramonte, M., Graves, M., Thomas, H.C., Hill, A.V., Thursz, M.R. Genes Immun. (2003) [Pubmed]
  5. Inducible expression of the 2-5A synthetase/RNase L system results in inhibition of vaccinia virus replication. Díaz-Guerra, M., Rivas, C., Esteban, M. Virology (1997) [Pubmed]
  6. mRNA levels and methylation patterns of the 2-5A synthetase gene in control and Alzheimer's disease (AD) fibroblasts. An, S., Khanna, K.K., Wu, J.M. Biochem. Mol. Biol. Int. (1994) [Pubmed]
  7. Crystal structure of the 2'-specific and double-stranded RNA-activated interferon-induced antiviral protein 2'-5'-oligoadenylate synthetase. Hartmann, R., Justesen, J., Sarkar, S.N., Sen, G.C., Yee, V.C. Mol. Cell (2003) [Pubmed]
  8. Effects of interferon alpha on autocrine growth factor loops in B lymphoproliferative disorders. Heslop, H.E., Bianchi, A.C., Cordingley, F.T., Turner, M., Chandima, W., De Mel, C.P., Hoffbrand, A.V., Brenner, M.K. J. Exp. Med. (1990) [Pubmed]
  9. A direct comparison of biological response modulation and clinical side effects by interferon-beta ser, interferon-gamma, or the combination of interferons beta ser and gamma in humans. Schiller, J.H., Storer, B., Paulnock, D.M., Brown, R.R., Datta, S.P., Witt, P.L., Borden, E.C. J. Clin. Invest. (1990) [Pubmed]
  10. Downregulation of interferon alpha but not gamma receptor expression in vivo in the acquired immunodeficiency syndrome. Lau, A.S., Read, S.E., Williams, B.R. J. Clin. Invest. (1988) [Pubmed]
  11. Truncation does not abrogate transcriptional downregulation of the c-myc gene by sodium butyrate in Burkitt's lymphoma cells. Polack, A., Eick, D., Koch, E., Bornkamm, G.W. EMBO J. (1987) [Pubmed]
  12. Effects of retinoids and interferon-gamma on cultured breast cancer cells in comparison with tumor necrosis factor alpha. Marth, C., Zech, J., Böck, G., Mayer, I., Daxenbichler, G. Int. J. Cancer (1987) [Pubmed]
  13. 2'-,5'-Oligoadenylate synthetase response ratio predicting virological response to PEG-interferon-alpha2b plus ribavirin therapy in patients with chronic hepatitis C. Kim, K.I., Kim, S.R., Sasase, N., Taniguchi, M., Harada, S., Kinoshita, K., Kim, S.H., Akimoto, Y., Shikata, M., Kimura, N., Izawa, S., Ohtani, A., Nakao, K., Motojima, M., Kinoshita, M., Hirai, M., Ohzu, M., Hirooka, T., Nabeshima, S., Ishii, F., Tanaka, K., Hotta, H. Journal of clinical pharmacy and therapeutics. (2006) [Pubmed]
  14. Enhancement of natural killer cell activity and 2-5A synthetase in operable breast cancer patients treated with polyadenylic; polyuridylic acid. Hovanessian, A.G., Youn, J.K., Buffet-Janvresse, C., Riviere, Y., Michelson, M., Lacour, J., Lacour, F. Cancer (1985) [Pubmed]
  15. Ampligen treatment of renal cell carcinoma: changes in 2-5A synthetase, 2-5A oligomer size and natural killer cell activity associated with antitumor response clinically. Suhadolnik, R.J., Reichenbach, N.L., Lee, C., Strayer, D.R., Brodsky, I., Carter, W.A. Prog. Clin. Biol. Res. (1985) [Pubmed]
  16. Variation in antiviral 2',5'-oligoadenylate synthetase (2'5'AS) enzyme activity is controlled by a single-nucleotide polymorphism at a splice-acceptor site in the OAS1 gene. Bonnevie-Nielsen, V., Field, L.L., Lu, S., Zheng, D.J., Li, M., Martensen, P.M., Nielsen, T.B., Beck-Nielsen, H., Lau, Y.L., Pociot, F. Am. J. Hum. Genet. (2005) [Pubmed]
  17. The Mammalian 2'-5' oligoadenylate synthetase gene family: evidence for concerted evolution of paralogous oas1 genes in rodentia and artiodactyla. Perelygin, A.A., Zharkikh, A.A., Scherbik, S.V., Brinton, M.A. J. Mol. Evol. (2006) [Pubmed]
  18. The human 2',5'-oligoadenylate synthetase locus is composed of three distinct genes clustered on chromosome 12q24.2 encoding the 100-, 69-, and 40-kDa forms. Hovnanian, A., Rebouillat, D., Mattei, M.G., Levy, E.R., Marié, I., Monaco, A.P., Hovanessian, A.G. Genomics (1998) [Pubmed]
  19. Cloning and chromosomal location of human genes inducible by type I interferon. Wathelet, M.G., Szpirer, J., Nols, C.B., Clauss, I.M., De Wit, L., Islam, M.Q., Levan, G., Horisberger, M.A., Content, J., Szpirer, C. Somat. Cell Mol. Genet. (1988) [Pubmed]
  20. Human 2-5A synthetase: characterization of a novel cDNA and corresponding gene structure. Saunders, M.E., Gewert, D.R., Tugwell, M.E., McMahon, M., Williams, B.R. EMBO J. (1985) [Pubmed]
  21. Full-length sequence and expression of the 42 kDa 2-5A synthetase induced by human interferon. Wathelet, M., Moutschen, S., Cravador, A., DeWit, L., Defilippi, P., Huez, G., Content, J. FEBS Lett. (1986) [Pubmed]
  22. Structure and expression of a cloned cDNA for human (2'-5')oligoadenylate synthetase. Shiojiri, S., Fukunaga, R., Ichii, Y., Sokawa, Y. J. Biochem. (1986) [Pubmed]
  23. Immune interferon inhibits proliferation and induces 2'-5'-oligoadenylate synthetase gene expression in human vascular smooth muscle cells. Warner, S.J., Friedman, G.B., Libby, P. J. Clin. Invest. (1989) [Pubmed]
  24. Type 1 diabetes and the OAS gene cluster: association with splicing polymorphism or haplotype? Tessier, M.C., Qu, H.Q., Fréchette, R., Bacot, F., Grabs, R., Taback, S.P., Lawson, M.L., Kirsch, S.E., Hudson, T.J., Polychronakos, C. J. Med. Genet. (2006) [Pubmed]
  25. Biological and clinical effects of the combination of beta- and gamma-interferons administered as a 5-day continuous infusion. Schiller, J.H., Storer, B., Witt, P.L., Nelson, B., Brown, R.R., Horisberger, M., Grossberg, S., Borden, E.C. Cancer Res. (1990) [Pubmed]
  26. A type I interferon signaling factor, ISF21, encoded on chromosome 21 is distinct from receptor components and their down-regulation and Is necessary for transcriptional activation of interferon-regulated genes. Holland, K.A., Owczarek, C.M., Hwang, S.Y., Tymms, M.J., Constantinescu, S.N., Pfeffer, L.M., Kola, I., Hertzog, P.J. J. Biol. Chem. (1997) [Pubmed]
  27. Influence of interferon beta-1a dose frequency on PBMC cytokine secretion and biological effect markers. Rothuizen, L.E., Buclin, T., Spertini, F., Trinchard, I., Munafo, A., Buchwalder, P.A., Ythier, A., Biollaz, J. J. Neuroimmunol. (1999) [Pubmed]
  28. Microwave exposure alters the expression of 2-5A-dependent RNase. Krause, D., Mullins, J.M., Penafiel, L.M., Meister, R., Nardone, R.M. Radiat. Res. (1991) [Pubmed]
  29. Effects of human gamma interferon on cell growth, replication of virus and induction of 2'-5'oligoadenylate synthetase in three human lymphoblastoid cell lines and K562 cells. Tomita, Y., Cantell, K., Kuwata, T. Int. J. Cancer (1982) [Pubmed]
  30. OAS1 gene haplotype confers susceptibility to multiple sclerosis. Fedetz, M., Matesanz, F., Caro-Maldonado, A., Fernandez, O., Tamayo, J.A., Guerrero, M., Delgado, C., L??pez-Guerrero, J.A., Alcina, A. Tissue Antigens (2006) [Pubmed]
  31. The in vitro antiviral activity of tumor necrosis factor (TNF) in WISH cells is mediated by IFN-beta induction. Ruggiero, V., Antonelli, G., Conciatori, G., Gentile, M., Van Damme, J., Dianzani, F. Antiviral Res. (1989) [Pubmed]
  32. Inhibition of 2'-5' oligoadenylate synthetase by divalent metal ions. Hartmann, R., Walko, G., Justesen, J. FEBS Lett. (2001) [Pubmed]
  33. Dynamics of interferon-specific gene expression in peripheral blood of interferon alfa-naïve patients with genotype 1 chronic hepatitis C infection treated with albumin-interferon alfa. Bain, V.G., Yoshida, E.M., Kaita, K.D., Swain, M.G., Heathcote, E.J., Garcia, A., Moore, P.A., Yu, R., McHutchison, J.G., Subramanian, G.M. Hepatol. Res. (2006) [Pubmed]
  34. OAS1 splice site polymorphism controlling antiviral enzyme activity influences susceptibility to type 1 diabetes. Field, L.L., Bonnevie-Nielsen, V., Pociot, F., Lu, S., Nielsen, T.B., Beck-Nielsen, H. Diabetes (2005) [Pubmed]
  35. Three-dimensional models of human 2'-5' oligoadenylate synthetases: a new computational method for reconstructing an enzyme assembly. Torshin, I.Y. Med. Sci. Monit. (2005) [Pubmed]
  36. Short-term cytotoxic effects and long-term instability of RNAi delivered using lentiviral vectors. Fish, R.J., Kruithof, E.K. BMC Mol. Biol. (2004) [Pubmed]
  37. RNA drug therapy acting via the 2-5A synthetase/RNase L pathway. Suhadolnik, R.J., Reichenbach, N.L., Hitzges, P.M., Ablashi, D.V., Strayer, D.R., Carter, W.A. Ann. N. Y. Acad. Sci. (1993) [Pubmed]
  38. Basal and interferon-induced 2',5'-oligoadenylate synthetase in human monocytes, lymphocytes, and peritoneal macrophages. Witt, P.L., Spear, G.T., Helgeson, D.O., Lindstrom, M.J., Smalley, R.V., Borden, E.C. J. Interferon Res. (1990) [Pubmed]
WikiGenes - Universities